RESUMEN
Polyunsaturated fatty acids (PUFAs) include two series of fatty acids: omega-6 and omega-3 series. PUFAs have amphiphatic properties: hydrophilic head and hydrophobic tail. Such structure and other properties of unsaturated fatty acids are responsible for exerting the following biological action: maintaining cell-membrane fluidity, inhib- iting inflammatory processes, decreasing secretion of proinflammatory cytokines by monocytes/macrophages, decreasing susceptibility to ventricular rhythm disorders of the heart, improving functions of vascular endothe- lial cells, inhibiting blood platelet aggregation and decreasing triglyceride synthesis in the liver. In an organism, aracidonic acid (ARA) is converted to prostanoids series 2 (PGE2, PGI2, TXA2) and leukotrienes series 4 (LTB4, LTC4, LTD4) which are endowed with pro-inflammatory potential and are able to induce platelet aggregation and vasoconstriction. The metabolism of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) gives prostanoids series 3 (PGE3, PGI3, TXA3) and leukotrienes series 5 (LTB5, LTC5, LTD5); this group of eicosanoids shows anti-inflammatory, antiplatelet and antiarrhythmic properties.
Asunto(s)
Ácidos Grasos Insaturados/farmacología , Animales , Dieta , Suplementos Dietéticos , Ácidos Grasos Insaturados/química , Ácidos Grasos Insaturados/metabolismo , Humanos , Estructura Molecular , Ingesta Diaria Recomendada , Transducción de Señal , Relación Estructura-ActividadRESUMEN
Paracetamol/acetaminophen is one of the most popular and most commonly used analgesic and antipyretic drugs around the world, available without a prescription, both in mono- and multi-component preparations. It is the drug of choice in patients that cannot be treated with non-steroidal anti-inflammatory drugs (NSAID), such as people with bronchial asthma, peptic ulcer disease, hemophilia, salicylate-sensitized people, children under 12 years of age, pregnant or breastfeeding women. It is recommended as a first-line treatment of pain associated with osteoarthritis. The mechanism of action is complex and includes the effects of both the peripheral (COX inhibition), and central (COX, serotonergic descending neuronal pathway, L-arginine/NO pathway, cannabinoid system) antinociception processes and "redox" mechanism. Paracetamol is well tolerated drug and produces few side effects from the gastrointestinal tract, however, despite that, every year, has seen a steadily increasing number of registered cases of paracetamol-induced liver intoxication all over the world. Given the growing problem of the safety of acetaminophen is questioned the validity of the sale of the drug without a prescription. This work, in conjunction with the latest reports on the mechanism of action of paracetamol, trying to point out that it is not a panacea devoid of side effects, and indeed, especially when is taken regularly and in large doses (> 4 g/day), there is a risk of serious side effects.
Asunto(s)
Acetaminofén/uso terapéutico , Analgésicos no Narcóticos/uso terapéutico , Acetaminofén/efectos adversos , Acetaminofén/farmacología , Animales , HumanosRESUMEN
AMD (age-related macular degeneration) is a progressive vision-threatening ocular disease, affecting central region of the retina--the macula--and manifesting in the elderly. AMD is a degenerative disease, and the degeneration affects primarily the retinal pigment epithelial (RPE) cells and secondarily the photoreceptors, leading consequently to disturbances or partial loss of central vision and legal blindness. Clinically, the disease is classified as: atrophic--dry AMD (in majority of cases), and neovascular--wet AMD (with choroidal neovascularization--CNV: 10-15% of all AMD cases). Pathogenesis of AMD is complex, multifactorial and only poorly recognized. Main risk factors include: advanced age, genetic predispositions, environmental determinants, history of exposure to intensive light and smoking. At least four molecular processes contribute to the development of AMD pathology: lipofuscinogenesis, drusogenesis, inflammation and choroidal neovascularization (in wet AMD). Since vascular endothelial growth factor (VEGF) is a predominant proangiogenic factor in CNV. the wet AMD can be treated with intravitreous application of "anti-VEGF" agents (Avastin, Lucentis, Eylea). Till now, there is no approved therapy for dry AMD, although several agents/treatments are currently in clinical trials. This paper briefly describes major molecular and cellular events leading to AMD, and presents currently used and new experimental therapeutic strategies against AMD.
Asunto(s)
Degeneración Macular/tratamiento farmacológico , Degeneración Macular/etiología , Inhibidores de la Angiogénesis/administración & dosificación , Inhibidores de la Angiogénesis/uso terapéutico , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Neovascularización Coroidal/complicaciones , Neovascularización Coroidal/tratamiento farmacológico , Neovascularización Coroidal/inmunología , Neovascularización Coroidal/metabolismo , Ensayos Clínicos como Asunto , Suplementos Dietéticos , Humanos , Degeneración Macular/inmunología , Degeneración Macular/metabolismo , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/uso terapéutico , Estrés Oxidativo/efectos de los fármacos , Fotoquimioterapia/métodos , Factores de Riesgo , Trasplante de Células Madre/métodos , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidoresRESUMEN
Osteoarthritis (ostheoarthrosis, OA) is characterized by progressive destruction of articular cartilage, remodeling of the periarticular bone and inflammation of the synovial membrane. In patients occur joints pain, impaired joints motion and disability. The results of many studies indicate an inflammation as foundation of this disease. The management of OA include a combination of pharmacological treatments and nonpharmacological interventions. Pharmacological treatments include used paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs) and chondroprotectives (glucosamine, chondroitin sulfate and so on). NSAIDs long-term use associated with serious adverse effects. OA symptoms are effectively reduced by nutrients such omega 3 and omega 6 fatty acids (PUFAs as EPA, DHA), which decrease the need for non-steroidal drugs and may less adverse events. They exerts, particularly EPA, anti-inflammatory effect, inhibit catabolic processes, stimulate the anabolic process in the cartilage in the joint. Many different evidence validate that omega 3 alleviate the progression of osteoarthritis and have exciting therapeutic potential for preventing cartilage degradation associated with chronic inflammatory in joints.
Asunto(s)
Ácidos Grasos Omega-3/uso terapéutico , Ácidos Grasos Omega-6/uso terapéutico , Osteoartritis/tratamiento farmacológico , Acetaminofén/uso terapéutico , Antiinflamatorios/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Sulfatos de Condroitina/uso terapéutico , Progresión de la Enfermedad , Glucosamina/uso terapéutico , HumanosRESUMEN
Inflammation is a physiological defense reaction of living tissues to injury or infection. An array of mediators, including those derived from omega-6 (omega6) polyunsaturated fatty acids (PUFAs), such as arachidonic acid (AA) e.g. prostaglandins and leukotrienes, promote the inflammatory response. Acute inflammation has several programmed fates, including complete resolution or progression to chronic inflammation, scarring, and eventual loss of tissue function. Studies on AA-derived proinflammatory mediators led to the discovery of AA-derived anti-inflammatory and pro-resolving compounds. These include lipoxins, originating from AA, and resolvins, originating from the omega-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as well as the omega-6 PUFA docosapentaenoic acid (DPA-omega6). DHA is also a substrate for other anti-inflammatory mediators, i.e. neuroprotectin and maresin. Because of their role in the final phase of acute inflammation, i.e. the resolution of inflammation, the above anti-inflammatory mediators were named pro-resolving mediators. They are formed in cooperating cells present in the region of inflammation in a process called transcellular biosynthesis with the aid of specific lipoxygenases (LOX) and cyclooxygenases (COX). Pro-resolving anti-inflammatory mediators exert their biological activities in a receptor-dependent manner in the resolution phase of inflammation. Of their various biological effects, the most important include inhibition of leukocyte mobilization and traffic through endothelial or epithelial layers, suppression of proinflammatory cytokine release by different cells present in inflamed tissue, and stimulation of the phagocytic activity of monocytes/macrophages. This article surveys the current knowledge on inflammation and the role of the pro-resolving and anti-inflammatory potential of lipid-derived agonistic mediators.
Asunto(s)
Ácidos Grasos Omega-3/metabolismo , Ácidos Grasos Omega-6/metabolismo , Inflamación/metabolismo , Antiinflamatorios , Antígenos CD59/metabolismo , Humanos , Inflamación/fisiopatología , Mediadores de Inflamación/metabolismo , Lipoxinas/metabolismoRESUMEN
Effects of histamine (HA) on cyclic AMP production and its action upon the effects evoked by vasoactive intestinal peptide (VIP) were studied in the chick hypothalamus. HA (0.1-1000 microM) potently stimulated cyclic AMP formation in the hypothalamic slices, reaching maximal effect (2.5-3.5-fold increase) at a 100 microM concentration, and displaying an EC50 value of approximately 6.5 microM/ The stimulatory action of HA was mimicked by agonists of HA receptors, with the following rank order of potency: HA>4-methylHA (H2)>or=Nalpha,Nalpha-dimethylHA (H3>>H1=H2)>or=2-methylHA (H1)>>amthamine (H2)>>dimaprit (H2) approximately tele-methylHA. The HA (100 microM)-evoked increase in cyclic AMP production was concentration-dependently antagonized by selective H2-HA receptor blockers (aminopotentidine>>cimetidine>or=ranitidine>>zolantadine) and was not affected by mepyramine and thioperamide, a selective H1- and H3-HA receptor antagonist, respectively. The pharmacological profile of HA receptors linked to the cyclic AMP-generating system in the chick hypothalamus indicates that they represent either an avian-specific H2-like HA receptor or a novel subtype of HA receptors. Chicken VIP (cVIP; 0.1-3 microM) potently stimulated cyclic AMP synthesis in the chick hypothalamus in a concentration-dependent manner. A combination of cVIP with HA produced cyclic AMP response more than additive, and such a synergistic interaction was antagonized by ranitidine. It is suggested that in the avian brain HA and VIP may play in concert to regulate neuroendocrine processes.
Asunto(s)
AMP Cíclico/biosíntesis , Histamina/metabolismo , Hipotálamo/efectos de los fármacos , Péptido Intestinal Vasoactivo/metabolismo , Animales , Pollos , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Agonistas de los Receptores Histamínicos/farmacología , Antagonistas de los Receptores Histamínicos/farmacología , Hipotálamo/metabolismo , Técnicas In Vitro , Masculino , Receptores Histamínicos/metabolismoRESUMEN
Vasoactive intestinal peptide (chicken form; chVIP), peptide histidine-isoleucine (porcine and rat forms; pPHI and rPHI), D-Phe(4) derivative of porcine PHI (D-Phe(4)-pPHI), peptide histidine-methionine (PHM; human PHI), and helodermin, were tested for their ability to stimulate cAMP production in [(3)H]adenine-prelabeled slices of chick cerebral cortex (CCx) and hypothalamus (HTh). The chVIP (0.1-3 microM) concentration-dependently and potently stimulated cAMP production in HTh and CCx; the responses observed after 3 microM of chVIP were comparable to those produced by 0.1 microM PACAP38. Helodermin (5 microM) moderately but significantly stimulated cAMP formation in both HTh and CCx, whereas pPHI, rPHI, PHM at 5 microM concentration only weakly affected cAMP production in CCx, and were inactive in HTh; D-Phe(4)-pPHI was inactive in both tissues. These data demonstrate that chVIP, PACAP, and to a lesser extent helodermin were capable of potently stimulating cAMP generation in the avian central nervous system. PHI-related peptides showed only weak or no activity, depending on the tissue.
Asunto(s)
Pollos , AMP Cíclico/biosíntesis , Péptido PHI/farmacología , Isoformas de Proteínas/farmacología , Péptido Intestinal Vasoactivo/farmacología , Animales , Radioisótopos de Carbono , Células Cultivadas , Corteza Cerebral/citología , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Relación Dosis-Respuesta a Droga , Humanos , Hipotálamo/citología , Hipotálamo/efectos de los fármacos , Hipotálamo/metabolismo , Péptidos y Proteínas de Señalización Intercelular , Masculino , Neuropéptidos/metabolismo , Neuropéptidos/farmacología , Fragmentos de Péptidos/metabolismo , Fragmentos de Péptidos/farmacología , Péptido PHI/metabolismo , Péptidos/metabolismo , Péptidos/farmacología , Polipéptido Hipofisario Activador de la Adenilato-Ciclasa , Receptores de Péptido Intestinal Vasoactivo/efectos de los fármacos , Receptores de Péptido Intestinal Vasoactivo/fisiología , Análisis de Secuencia de Proteína , Porcinos , Tritio , Péptido Intestinal Vasoactivo/metabolismoRESUMEN
This study has demonstrated that the short and long form of the pituitary adenylate cyclase-activating polypeptide (PACAP), i.e. PACAP(27) and PACAP(38), moderately but significantly, and in a concentration (0.5-5 microM)-dependent manner, stimulated inositol phosphates (IPs) accumulation in myo-[(3)H]inositol-prelabeled cerebral cortical and hypothalamal slices of chick and duck, and in slices of rat cerebral cortex; both peptides had no effect on IPs formation in rat hypothalamus. Vasoactive intestinal peptide (VIP; 0.5-5 microM) weakly enhanced IPs accumulation in chick hypothalamus, had no significant action in chick cerebral cortex (in fact there was a tendency to attenuate the IPs response in this tissue), and slightly, but significantly, inhibited the IPs accumulation in rat cerebral cortex. VIP showed no activity in rat hypothalamus. It is concluded that the stimulatory action of PACAP on phosphoinositide metabolism in avian cerebral cortex, similar to rat cerebral cortex, is mediated via phospholipase C-linked PAC(1) type receptors. In chick hypothalamus, however, there may be a component of VPAC type receptors stimulating IPs formation.